Clinical Trials

Date: 2017-05-04

Type of information: Presentation of results at a congress

phase: preclinical

Announcement: presentation of results at the PEGS Third Annual Agonist Immunotherapy Targets conference in Boston

Company: Alligator Bioscience (Sweden)

Product: ADC-1013/JNJ-64457107

Action mechanism: monoclonal antibody. ADC-1013 is an agonistic fully human monoclonal antibody targeting CD40, an immunostimulatory receptor found on antigen-presenting cells such as dendritic cells. ADC-1013 has been developed in close collaboration with Professor Thomas Tötterman, Uppsala University, Sweden. Professor Tötterman is a pioneer in directed immunotherapy of cancer, a concept where the immune system is selectively activated locally in the tumor microenvironment in order to reduce systemic side effects while optimizing systemic anti-tumor effects. Professor Tötterman´s group has performed a number of successful in-vivo experiments demonstrating the powerful immune mediated anti-tumor effects of ADC-1013. The pre-clinical assessment of ADC-1013 indicates a favorable tolerability profile, which is likely to be further improved by the intratumoral route of administration in the first clinical trial. Manufacturing of ADC-1013 was performed by Cobra Biologics, using the maxXpress platform and the Ubiquitous Chromatin Opening Element (UCOE) technology, and by BioInvent International, who performed process development and manufacturing of the non-GMP and GMP batches.


Therapeutic area:


Trial details:

Latest news:

  • • On May 4, 2017, Alligator Bioscience presented new pre-clinical data on the CD40 agonistic immuno-oncology antibody, ADC-1013 at the PEGS Third Annual Agonist Immunotherapy Targets conference in Boston. Dr Peter Ellmark, Principal Scientist at Alligator, gave an oral presentation titled: “Tumor-Directed Immunotherapy – Tumor-Localized Immune Activation Using TNFR-SF Agonistic Antibodies” and the key data follows.
  • ADC-1013, licensed to Janssen Biotech, was shown to induce synergistic anti-tumor effects in combination with PD-1 receptor blockade in a pre-clinical bladder cancer model. Moreover, ADC-1013 indicated the potential to augment the effect of cancer vaccines in a lymphoma model. “The new data supports that ADC-1013 may act synergistically with other immunotherapies, notably PD-1 checkpoint blockade and cancer vaccines, and holds great promise for the clinical programme.” says Per Norlén, CEO at Alligator Bioscience.

Is general: Yes